Benchmark raised the firm’s price target on Unicycive Therapeutics (UNCY) to $21 from $3 and keeps a Speculative Buy rating on the shares, noting that the firm’s new price target reflects a 1:10 reverse split and an updated discount rate after Unicycive said that it plans to complete a Type A meeting with the FDA to gain alignment on the best strategy to resolve the remaining issues outlined in the complete response letter for the oxylanthanum carbonate New Drug Application.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Faces Class Action Over FDA Misleading Claims
- Unicycive Faces Securities Lawsuit Over Drug Claims
- Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKD
- Unicycive Therapeutics Raises $16.3 Million in Stock Sale
- Unicycive Therapeutics: Buy Rating Amid FDA Compliance Resolution and Strong Financial Position